LSD1-IN-34

• UNSPSC Description:

  LSD1-IN-34 (Compound 7d) is the orally active inhibitor for Lysine-specific demethylase (LSD) and monoamine oxidase (MAO), with IC50 of 4.51 and 18.46 nM, for LSD1 and MAO A. LSD1-IN-34 inhibits the Ang II-induced neonatal rat myocardial fibroblasts (NRCFs) activation, without significant toxicity (20 μM). LSD1-IN-34 inhibits TGFβ/Smad signaling pathway, and ameliorates heart failure in mice. LSD1-IN-34 exhibits good pharmacokinetic characteristics in rats[1].

• Target Antigen:

  Histone Demethylase; Monoamine Oxidase; TGF-beta/Smad

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;Neuronal Signaling;Stem Cell/Wnt;TGF-beta/Smad

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/lsd1-in-34.html

• Smiles:

  FC1=CC([C@H]2[C@H](NCC3=CN(C4=CC=C(OCO5)C5=C4)N=N3)C2)=CC=C1F.Cl

• Molecular Weight:

  406.81

• References & Citations:

  [1]Huang MJ, et al., Design, Synthesis, and Evaluation of the Selective and Orally Active LSD1 Inhibitor with the Potential of Treating Heart Failure. J Med Chem. 2024 Aug 8;67(15):13409-13434.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported